ArticlePloS one2013
Serum amyloid P is a sialylated glycoprotein inhibitor of influenza A viruses.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- Screening of Low-Tumorigenic MDCK Cells for Potential Influenza Vaccine Substrates and Transcriptomic Analyses.International journal of molecular sciences · 2026Article
- Review
- Article
- Novel Selective Quantification of Zinpentraxin Alfa Biotherapeutic in the Presence of Endogenous Isomer in Plasma Samples of Idiopathic Pulmonary Fibrosis Patients Using Immunoaffinity LC-MS.The AAPS journal · 2023Article
- Immunological Correlates of Prevention of the Onset of Seasonal H3N2 Influenza.The Journal of infectious diseases · 2022Article
- Clinical significance of differential serum-signatures for early prediction of severe dengue among Eastern Indian patients.Clinical and experimental immunology · 2022Article
- Antibodies directed towards neuraminidase restrict influenza virus replication in primary human bronchial epithelial cells.PloS one · 2022Article
- Effects of serum amyloid protein A on influenza A virus replication and viral interactions with neutrophils.Journal of leukocyte biology · 2021Article
- Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus.Nature communications · 2021Article
- Exosome therapeutics for COVID-19 and respiratory viruses.View (Beijing, China) · 2021Review
- Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice.PloS one · 2021Article
- Complementary Roles of Short and Long Pentraxins in the Complement-Mediated Immune Response toFrontiers in immunology · 2021Review
- Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.The Lancet. Respiratory medicine · 2020Review
- Zebrafish C-reactive protein isoforms inhibit SVCV replication by blocking autophagy through interactions with cell membrane cholesterol.Scientific reports · 2020Article
- Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19.Frontiers in cellular and infection microbiology · 2020Review
- Acute phase protein response to viral infection and vaccination.Archives of biochemistry and biophysics · 2019Review
- Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.Nature microbiology · 2019Article
- Effect of fetal calf serum on propagation of duck hepatitis A virus genotype 3 in duck embryo fibroblast cells.BMC veterinary research · 2019Article
- Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.Journal of virology · 2018Article
- The Role and Molecular Mechanism of Action of Surfactant Protein D in Innate Host Defense Against Influenza A Virus.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Members of the pentraxin family, including PTX3 and serum amyloid P component (SAP), have been reported to play a role in innate host defence against a range of microbial pathogens, yet little is known regarding their antiviral activities. In this study, we demonstrate that human SAP binds to human influenza A virus (IAV) strains and mediates a range of antiviral activities, including inhibition of IAV-induced hemagglutination (HA), neutralization of virus infectivity and inhibition of the enzymatic activity of the viral neuraminidase (NA). Characterization of the anti-IAV activity of SAP after periodate or bacterial sialidase treatment demonstrated that α(2,6)-linked sialic acid residues on the glycosidic moiety of SAP are critical for recognition by the HA of susceptible IAV strains. Other proteins of the innate immune system, namely human surfactant protein A and porcine surfactant protein D, have been reported to express sialylated glycans which facilitate inhibition of particular IAV strains, yet the specific viral determinants for recognition of these inhibitors have not been defined. Herein, we have selected virus mutants in the presence of human SAP and identified specific residues in the receptor-binding pocket of the viral HA which are critical for recognition and therefore susceptibility to the antiviral activities of SAP. Given the widespread expression of α(2,6)-linked sialic acid in the human respiratory tract, we propose that SAP may act as an effective receptor mimic to limit IAV infection of airway epithelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.